Independent research led by the Olympic World Library last year confirmed that as long as emissions are reduced or stabilised ...

The FDA delivered a pair of holiday season approvals a week apart, signing off on Agios’ oral medicine Aqvesme for the treatment of anemia in adults with alpha- or beta-thalassemia on Dec. 23, and ...

In a saga that has spread over seven years, the FDA has again rejected Vanda’s bid to expand the label for Hetlioz to treat jet lag disorder. The new thumbs-down came Wednesday, three months after the ...

Vanda said the FDA approved NEREUS (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. The approval marks the first new pharmacologic ...

Vanda Pharmaceuticals (VNDA) lost ~11% in the premarket on Thursday after the U.S. FDA declined to approve a label expansion for its sleep disorder drug Hetlioz (tasimelteon) as a treatment for jet ...

B. Riley raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $14 from $11 and keeps a Buy rating on the shares after the FDA approved Nereus for prevention of vomiting induced by motion ...

Vanda Pharmaceuticals (VNDA) added ~21% in the premarket on Wednesday after the U.S. FDA approved its motion sickness therapy Nereus (tradipitant), developed in partnership with Eli Lilly (LLY).

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares are trending on Wednesday. Check out the current price of VNDA stock here. Shares of the biopharmaceutical company jumped 20.20% to $8.45 in ...

The FDA's decision was backed by data from three pivotal clinical trials, where tradipitant reduced the incidence of vomiting and showed a safety profile considered compatible with acute use. The drug ...

Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has approved Vanda Pharmaceuticals’ Nereus (tradipitant) for the prevention of vomiting ...

Investing.com - Jefferies has raised its price target on Vanda Pharmaceuticals (NASDAQ:VNDA) to $7.50 from $5.00 while maintaining a Hold rating on the stock. Currently trading at $7.03, the $415 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The rejection came just a week ...